Provectus Biopharmaceuticals (PVCT)
(Delayed Data from OTC)
$0.11 USD
+0.01 (4.76%)
Updated Jul 29, 2024 03:52 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PVCT 0.11 +0.01(4.76%)
Will PVCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PVCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for PVCT
Provectus Pharmaceuticals Shares Annual Progress Update
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
Provectus announces presentation at RBS for full-thickness cutaneous wounds
Provectus: Q1 Earnings Snapshot